Shield Therapeutics (Shield Therapeutics) 3-Year EBITDA Growth Rate : -43.60% (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Shield Therapeutics 3-Year EBITDA Growth Rate?

Shield Therapeutics's EBITDA per Share for the six months ended in Jun. 2023 was $-0.02.

During the past 3 years, the average EBITDA Per Share Growth Rate was -43.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shield Therapeutics was 66.40% per year. The lowest was -63.20% per year. And the median was 18.80% per year.

Competitive Comparison of Shield Therapeutics's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's 3-Year EBITDA Growth Rate falls into.

Shield Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shield Therapeutics (OTCPK:SHIEF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shield Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (Shield Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (OTCPK:SHIEF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

STX:UK 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.

Shield Therapeutics (Shield Therapeutics) Headlines

From GuruFocus

Full Year 2023 Shield Therapeutics PLC Trading Statement Presentation Transcript

By GuruFocus Research • 03-01-2024